ATE223218T1 - Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur - Google Patents

Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur

Info

Publication number
ATE223218T1
ATE223218T1 AT95119452T AT95119452T ATE223218T1 AT E223218 T1 ATE223218 T1 AT E223218T1 AT 95119452 T AT95119452 T AT 95119452T AT 95119452 T AT95119452 T AT 95119452T AT E223218 T1 ATE223218 T1 AT E223218T1
Authority
AT
Austria
Prior art keywords
ranolazine
piperazines
skeleton muscles
protecting
protecting skeleton
Prior art date
Application number
AT95119452T
Other languages
English (en)
Inventor
Robert J Dow
Pierre Ferrandon
Original Assignee
Syntex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Llc filed Critical Syntex Llc
Application granted granted Critical
Publication of ATE223218T1 publication Critical patent/ATE223218T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT95119452T 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur ATE223218T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37043589A 1989-06-23 1989-06-23

Publications (1)

Publication Number Publication Date
ATE223218T1 true ATE223218T1 (de) 2002-09-15

Family

ID=23459660

Family Applications (3)

Application Number Title Priority Date Filing Date
AT95119452T ATE223218T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
AT90111787T ATE142497T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
AT95119463T ATE218344T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von schockzuständen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT90111787T ATE142497T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
AT95119463T ATE218344T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von schockzuständen

Country Status (13)

Country Link
US (2) US5506229A (de)
EP (3) EP0719558B1 (de)
JP (1) JP3232085B2 (de)
AT (3) ATE223218T1 (de)
AU (1) AU633589B2 (de)
CA (1) CA2019580C (de)
DE (3) DE69028457T2 (de)
DK (3) DK0714660T3 (de)
ES (3) ES2182863T3 (de)
GR (1) GR3020976T3 (de)
IE (1) IE80710B1 (de)
NZ (2) NZ234184A (de)
ZA (1) ZA904842B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
WO1999007354A2 (en) * 1997-08-08 1999-02-18 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
WO2001060348A2 (en) * 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
EP1259493A2 (de) * 2000-02-22 2002-11-27 Cv Therapeutics, Inc. Substituierte piperazin-verbindungen
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677343B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
AU2001239827A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
AU2001285245A1 (en) * 2000-08-25 2002-03-13 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US7125876B2 (en) 2002-12-05 2006-10-24 Cv Therapeutics, Inc. Substituted heterocyclic compounds
ATE443058T1 (de) 2003-01-03 2009-10-15 Cv Therapeutics Inc Substituierte heterozyklische verbindungen
KR20050092424A (ko) 2003-01-17 2005-09-21 씨브이 쎄러퓨틱스, 인코포레이티드 심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물
WO2005000826A1 (en) 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
WO2005061470A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
WO2006029179A2 (en) * 2004-09-08 2006-03-16 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
JP2008519770A (ja) * 2004-11-09 2008-06-12 シーブイ・セラピューティクス・インコーポレイテッド 心不全の処置における左室リモデリングを逆転させるための少なくとも１種のリモデリング物質と併用するラノラジンの使用
US20060177502A1 (en) * 2005-01-06 2006-08-10 Srikonda Sastry Sustained release pharmaceutical formulations
EP1865945A4 (de) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd Kombinationstherapie bei endothel-dysfunktion, angina und diabetes
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
CA2678515A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
ES2402675T3 (es) * 2007-05-31 2013-05-07 Gilead Palo Alto, Inc. Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados
CA2713521A1 (en) * 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
AU2015200961B2 (en) * 2009-07-09 2017-02-16 Ozteo Pty Ltd Treatment of Non-Neuronal and Non-Cardiac Cell, Tissue and Organ Damage and Associated Pain with Persistent Sodium Current Blockers
WO2011003129A1 (en) * 2009-07-09 2011-01-13 Ozteo Pty Ltd Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers
US20120177729A1 (en) 2009-09-25 2012-07-12 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
CA2835293C (en) * 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101476379B1 (ko) * 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
KR101331186B1 (ko) * 2013-08-05 2013-11-22 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
CN116115669B (zh) * 2021-09-27 2025-05-06 天士力医药集团股份有限公司 一种治疗心肌缺血的药物组合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Also Published As

Publication number Publication date
IE902250A1 (en) 1991-01-16
EP0719558A1 (de) 1996-07-03
DE69028457T2 (de) 1997-02-20
ES2091211T3 (es) 1996-11-01
DE69033967T2 (de) 2002-12-19
DK0719558T3 (da) 2002-10-07
DK0407780T3 (da) 1996-09-30
CA2019580A1 (en) 1990-12-23
DE69034000T2 (de) 2003-06-05
IE80710B1 (en) 1998-12-16
NZ247044A (en) 1997-04-24
EP0407780A2 (de) 1991-01-16
US5506229A (en) 1996-04-09
IE902250L (en) 1990-12-23
EP0719558B1 (de) 2002-06-05
EP0714660B1 (de) 2002-09-04
EP0407780B1 (de) 1996-09-11
EP0714660A1 (de) 1996-06-05
DK0714660T3 (da) 2002-10-07
ES2177601T3 (es) 2002-12-16
CA2019580C (en) 2007-03-27
AU5761890A (en) 1991-01-03
AU633589B2 (en) 1993-02-04
NZ234184A (en) 1997-01-29
DE69033967D1 (de) 2002-07-11
ATE142497T1 (de) 1996-09-15
DE69034000D1 (de) 2002-10-10
ZA904842B (en) 1992-02-26
EP0407780A3 (en) 1992-01-02
ES2182863T3 (es) 2003-03-16
DE69028457D1 (de) 1996-10-17
GR3020976T3 (en) 1996-12-31
JP3232085B2 (ja) 2001-11-26
ATE218344T1 (de) 2002-06-15
US5906988A (en) 1999-05-25
JPH0348672A (ja) 1991-03-01

Similar Documents

Publication Publication Date Title
ATE223218T1 (de) Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
PT662958E (pt) Derivados do acido 1-(2-oxo-acetil)-piperidina-2-carboxilico como sensibilizadores de celulas cancerosas resistentes a farmacos multiplos
ATE110713T1 (de) Antihyperlipidemische und antiartherosklerotische harnstoffverbindungen.
DE3752200D1 (de) Verfahren zum Betrieb eines Mehrblattkollimators und Kompensators für Strahlentherapiegeräte
BR0014254A (pt) Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
DE3853546D1 (de) Vorrichtung zum Positionieren von Gliedmassen von Patienten und torischer chirurgischer Schild.
ATE92067T1 (de) 6-substituierte purinylpiperazinderivate.
ATE218329T1 (de) Anthracyclinon-derivate und ihre verwendung in amyloidose
MX9700807A (es) Derivados de 3-azabiciclo (3.2.0)heptano n-sustituidos utiles como neurolepticos.
DE3886621D1 (de) Bohrer für Handbohrmaschinen, Schraubbithalter und Verfahren zum Herstellen dieser Werkzeuge.
DE3063946D1 (en) Pesticidal agents containing substituted benzazoles and application thereof
NO991581L (no) N-(benzotiazol-2-yl)piperidin-1-etanaminderivater, deres fremstilling og anvendelse i terapeutiske midler
DK34087D0 (da) Acyltripeptid-forbindelser og deres anvendelse som immunostimulanter
NO146642C (no) Fremgangsmaate og middel ved inaktivering av ioniserbart sulfid i en broennborevaeske
ES460600A1 (es) Procedimiento de preparacion de aminoalcoxibenzofuranos.
ES8303307A1 (es) "un procedimiento para preparar derivados de urea y tiourea".
ATE232734T1 (de) Verwendung von pvp oder povidone zum reduzieren von darmschwellungen
NO904381L (no) Fremgangsmaate for fremstilling av nye inosin/guanosinderivater.
YU26783A (en) Process for the manufacture of the crystal alpha-form of 1-(4-amino-dimethoxy-2-quinazolinyl)4-(2-furoyl)-piperazine hydrochloride
PL242559A1 (en) Process for catalytic transformation of ethanoloamines into cyclic amines,especially morpholine,piperazine and triethylendiamine
ES1030678U (es) Maquina para la formacion de las embocaduras de acceso en las guias de persiana.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0714660

Country of ref document: EP

EELA Cancelled due to lapse of time